Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results

Key Points

• Lyell Immunopharma reported a quarterly loss of ($2.89) earnings per share, significantly missing the consensus estimate of ($0.19).
• Shares of Lyell Immunopharma closed at $10.57 on Tuesday, with a market capitalization of $163.41 million and a negative price-to-earnings ratio of -0.42.
• Acadian Asset Management LLC increased its stake in the company by 204.2% during the first quarter, now holding approximately 66.05% of the stock.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.80) by $0.91, Zacks reports. Lyell Immunopharma had a negative net margin of 514,649.22% and a negative return on equity of 73.66%. The company had revenue of $0.01 million during the quarter.

Lyell Immunopharma Stock Up 2.5%

Shares of LYEL traded up $0.26 during mid-day trading on Wednesday, reaching $10.83. 38,672 shares of the company's stock were exchanged, compared to its average volume of 85,683. The company has a 50-day simple moving average of $10.36 and a two-hundred day simple moving average of $10.41. Lyell Immunopharma has a 52-week low of $7.65 and a 52-week high of $32.40. The company has a market cap of $167.43 million, a price-to-earnings ratio of -0.43 and a beta of -0.19.

Institutional Trading of Lyell Immunopharma

An institutional investor recently raised its position in Lyell Immunopharma stock. AQR Capital Management LLC lifted its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 773.5% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 174,279 shares of the company's stock after acquiring an additional 154,327 shares during the quarter. AQR Capital Management LLC owned about 0.06% of Lyell Immunopharma worth $94,000 as of its most recent filing with the Securities and Exchange Commission. 66.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LYEL has been the subject of a number of research reports. HC Wainwright reaffirmed a "neutral" rating and issued a $10.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen upgraded shares of Lyell Immunopharma to a "hold" rating in a research report on Friday, June 6th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.